Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate.

Rein MS, Friedman AJ, Stuart JM, MacLaughlin DT

Fertility and sterility1 Jun 1990Cited by 49 (Europe PMC)

PMID2112489DOI10.1016/s0015-0282(16)53578-xPepBankPUB-02112489

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialMechanism
In women with fibroids, leuprolide increased fibroid estrogen receptor content versus placebo.
In plain wordsIn women with fibroids, leuprolide increased estrogen receptors in fibroids versus placebo.
Peptide
Leuprolide
Outcome
IncreaseFibroid estrogen receptor content
Study
n = 20
Comparator
Placebo
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg every 28 days for four injections · intramuscularAs given in this study (human).
Measurements
Estrogen receptor content
143.3 fmol/mg
leuprolide mean
Reported plus/minus value
22.8 fmol/mg
leuprolide
Estrogen receptor content
36.1 fmol/mg
placebo mean
Reported plus/minus value
14.3 fmol/mg
placebo
Source sentences
Summary
The mean fibroid ER content for GnRH-a-treated patients was significantly greater than in placebo-treated patients (143.3 +/- 22.8 versus 36.1 +/- 14.3 fmol/mg).
1 context sentence(design, population, supporting numbers)
Summary · context
Tissue was obtained from 20 premenopausal women with uterine fibroids who were randomized to receive either leuprolide acetate depot, 3.75 mg intramuscularly every 28 days for four injections (n = 10) or placebo (n = 10) before myomectomy.
Report a problemFND-0211248901
02HumanRandomized controlled trialMechanism
In women with fibroids, fibroid progesterone receptor content did not differ significantly between leuprolide and placebo.
In plain wordsIn women with fibroids, progesterone receptors in fibroids did not differ significantly between leuprolide and placebo.
Peptide
Leuprolide
Outcome
No significant changeFibroid progesterone receptor content
Study
n = 20
Comparator
Placebo
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg every 28 days for four injections · intramuscularAs given in this study (human).
Source sentences
Summary
The mean fibroid PR and the mean myometrial ER and PR content were not significantly different between treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Tissue was obtained from 20 premenopausal women with uterine fibroids who were randomized to receive either leuprolide acetate depot, 3.75 mg intramuscularly every 28 days for four injections (n = 10) or placebo (n = 10) before myomectomy.
Report a problemFND-0211248902
03HumanRandomized controlled trialMechanism
In women with fibroids, myometrial estrogen receptor content did not differ significantly between leuprolide and placebo.
In plain wordsIn women with fibroids, muscle estrogen receptors did not differ significantly between leuprolide and placebo.
Peptide
Leuprolide
Outcome
No significant changeMyometrial estrogen receptor content
Study
n = 20
Comparator
Placebo
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg every 28 days for four injections · intramuscularAs given in this study (human).
Source sentences
Summary
The mean fibroid PR and the mean myometrial ER and PR content were not significantly different between treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Tissue was obtained from 20 premenopausal women with uterine fibroids who were randomized to receive either leuprolide acetate depot, 3.75 mg intramuscularly every 28 days for four injections (n = 10) or placebo (n = 10) before myomectomy.
Report a problemFND-0211248903
04HumanRandomized controlled trialMechanism
In women with fibroids, myometrial progesterone receptor content did not differ significantly between leuprolide and placebo.
In plain wordsIn women with fibroids, muscle progesterone receptors did not differ significantly between leuprolide and placebo.
Peptide
Leuprolide
Outcome
No significant changeMyometrial progesterone receptor content
Study
n = 20
Comparator
Placebo
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 mg every 28 days for four injections · intramuscularAs given in this study (human).
Source sentences
Summary
The mean fibroid PR and the mean myometrial ER and PR content were not significantly different between treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Tissue was obtained from 20 premenopausal women with uterine fibroids who were randomized to receive either leuprolide acetate depot, 3.75 mg intramuscularly every 28 days for four injections (n = 10) or placebo (n = 10) before myomectomy.
Report a problemFND-0211248904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.